Blurbs

H.C. Wainwright Keeps Their Buy Rating on GeoVax Labs (GOVX)

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on GeoVax Labs (GOVXResearch Report) today and set a price target of $8.00. The company’s shares closed yesterday at $0.77.

Bernardino covers the Healthcare sector, focusing on stocks such as Geron, Artelo Biosciences, and Cassava Sciences. According to TipRanks, Bernardino has an average return of 19.4% and a 32.49% success rate on recommended stocks.

Currently, the analyst consensus on GeoVax Labs is a Moderate Buy with an average price target of $5.50, representing a 612.34% upside. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $3.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on GeoVax Labs’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $2.24 million. In comparison, last year the company earned a revenue of $79.71 thousand and had a GAAP net loss of $1.31 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and cancer using its novel vaccine platform. It focuses on human immunodeficiency virus, zika virus, hemorrhagic fever viruses, and malaria. The company was founded by Harriet Latham Robinson and Donald G. Hildebrand on September 9, 2006 and is headquartered in Smyrna, GA.

Read More on GOVX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More